Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]

Novel adoptive cell therapies for acute lymphoblastic leukaemia

Prof Rupert Handgretinger, Director and Chair, Children’s University Hospital...

Novel adoptive cell therapies for acute lymphoblastic leukaemia ( Prof Rupert Handgretinger, Director and Chair, Children’s University Hospital and Department of Haematology/Oncology, Tübingen, Germany )

Issues in allogeneic HSCT: Therapeutic options for post-transplant relapse

Prof David Marks - University Hospital Bristol, Bristol, UK

Issues in allogeneic HSCT: Therapeutic options for post-transplant relapse ( Prof David Marks - University Hospital Bristol, Bristol, UK )

CNS involvement and prophylaxis in acute lymphoblastic leukaemia

Dr Mark Litzow - Mayo Clinic, Rochester, USA

CNS involvement and prophylaxis in acute lymphoblastic leukaemia ( Dr Mark Litzow - Mayo Clinic, Rochester, USA )

Updates on bispecific T cell engagers (BiTEs) for the treatment of acute...

Prof Max Topp - University of Würzburg, Würzburg, Germany

Updates on bispecific T cell engagers (BiTEs) for the treatment of acute lymphoblastic leukaemia ( Prof Max Topp - University of Würzburg, Würzburg, Germany )

Using CAR T cells for the treatment of acute lymphoblastic leukaemia

Prof Claudia Rossig - Universität Münster, Münster, Germany

Using CAR T cells for the treatment of acute lymphoblastic leukaemia ( Prof Claudia Rossig - Universität Münster, Münster, Germany )

Myeloma bone disease: Clinical features and complications

Dr Andrew Chantry - University of Sheffield, Sheffield, UK

Myeloma bone disease: Clinical features and complications ( Dr Andrew Chantry - University of Sheffield, Sheffield, UK )

Should you start treatment early in smouldering multiple myeloma?

Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Barcelona, Spain

Should you start treatment early in smouldering multiple myeloma? ( Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Barcelona, Spain )

Assessing treatment options for multiple myeloma and managing lenalidomide...

Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France

$Assessing treatment options for multiple myeloma and managing lenalidomide-refractory disease ( Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France )$

Controversies in the management of prostate cancer

Prof Mach Roach III - University of California, San Francisco, USA

Controversies in the management of prostate cancer ( Prof Mach Roach III - University of California, San Francisco, USA )

Role of interventional oncology for immunology treatment

Prof Thierry De Baere - Institut Gustave Roussy, Paris, France

Role of interventional oncology for immunology treatment ( Prof Thierry De Baere - Institut Gustave Roussy, Paris, France )

Advanced HCC: New systemic treatment options

Prof Hesham El-Ghazaly - Ain Shams University, Cairo, Egypt

Advanced HCC: New systemic treatment options ( Prof Hesham El-Ghazaly - Ain Shams University, Cairo, Egypt )

First- and second-line treatments for locally advanced renal cell carcinoma

Prof Jorge A. Garcia - Cleveland Clinic, Cleveland, USA

First- and second-line treatments for locally advanced renal cell carcinoma ( Prof Jorge A. Garcia - Cleveland Clinic, Cleveland, USA )

More from ecancer